İsmail Şimşek

997 citations

54 papers · 697 indexed · h-index 16

Rheumatology top 5%
- Rheumatoid Arthritis Research and Therapies 18
- Systemic Lupus Erythematosus Research 9
- Spondyloarthritis Studies and Treatments 8
- Osteoarthritis Treatment and Mechanisms 6
Hematology top 10%
- Autoimmune and Inflammatory Disorders Research 5
Immunology
Pharmacology top 10%
Ophthalmology top 10%
- Ocular Diseases and Behçet’s Syndrome 6
Molecular Biology
- Inflammasome and immune disorders 7
Genetics
- Chronic Lymphocytic Leukemia Research 4

Co-authors: Hakan Erdem Ayhan Dinç Salih Pay Yusuf Yazıcı Sedat Yılmaz J. Tambiah Allan Gibofsky A. DiFrancesco
Cited by: Rheumatology Hematology Immunology
Journals: Annals of the Rheumatic Diseases (5 papers)Clinical Rheumatology (3 papers)Rheumatology and Therapy (3 papers)
Partner nations: Türkiye United States Serbia

In The Last Decade

İsmail Şimşek

52 papers receiving 680 citations

Peers

Countries citing papers authored by İsmail Şimşek

Since Specialization

Citations

This map shows the geographic impact of İsmail Şimşek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by İsmail Şimşek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites İsmail Şimşek more than expected).

Fields of papers citing papers by İsmail Şimşek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by İsmail Şimşek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by İsmail Şimşek. The network helps show where İsmail Şimşek may publish in the future.

Co-authorship network

The 25 scholars most cited alongside İsmail Şimşek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with İsmail Şimşek Line = papers co-authored together İsmail Şimşek links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients Clinical and Experimental Rheumatology ·Yusuf Yazıcı,J. Tambiah,Christopher J. Swearingen,Víctor A. López,Sarah J. Kennedy,Mark Fineman,İsmail Şimşek,S. D. Panfilova,Timothy E. McAlindon	2024	2
2	P104 Upregulation of both APRIL and BAFF in systemic lupus erythematosus suggests non-redundant roles, further revealed by potent dual inhibition with povetacicept (TACI vTD-Fc; ALPN-303) SHILAP Revista de lepidopterología ·Katherine E. Lewis,Domnic Udochi Nwanosike,Yobi,Tiffany C. Blair,Amanda Enstrom,Lawrence S. Evans,Armand Bankhead,İsmail Şimşek,Stanford L. Peng,Stacey R. Dillon	2024	1
3	Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study Rheumatology and Therapy ·Mark Fineman,Timothy E. McAlindon,Christian Lattermann,Christopher J. Swearingen,Sarah J. Kennedy,Víctor A. López,İsmail Şimşek,J. Tambiah,Yusuf Yazıcı	2023	3
4	PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) HemaSphere ·Catherine M. Broome,Donald M. Arnold,Caroline Piatek,Eun‐Ju Lee,Hany Zayed,Stanford L. Peng,İsmail Şimşek	2023	1
5	A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis Osteoarthritis and Cartilage ·Yusuf Yazıcı,T.E. McAlindon,Allan Gibofsky,Nancy E. Lane,Christian Lattermann,Nebojša Skrepnik,Hyo Jung Yoon,İsmail Şimşek,Heli Ghandehari,A. DiFrancesco,John P. Gibbs,J. Tambiah,M.C. Hochberg	2021	73
6	A descriptive analysis of real-world treatment patterns of innovator (Remicade<sup>®</sup>) and biosimilar infliximab in an infliximab-naïve Turkish population Biologics ·Yusuf Yazıcı,Lin Xie,孔繁峙,Lorie Ellis,Kavitha Goyal,Amanda Teeple,Ece Mutlu,İsmail Şimşek	2018	7
7	A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis Rheumatology International ·Muhammet Çınar,Sedat Yılmaz,Fatma İlknur Çınar,Süleyman Serdar Koca,Hakan Erdem,Salih Pay,Ayhan Dinç,Yusuf Yazıcı,İsmail Şimşek	2015	19
8	Autonomic functions in acrocyanosis assessed by heart rate variability European Journal of Rheumatology ·Sedat Yılmaz,Mehmet Yokuşoğlu,Muhammet Çınar,İsmail Şimşek,Oben Baysan,Bilgehan Savaş Öz,Hakan Erdem,Salih Pay,Ayhan Dinç	2014	1
9	A polymorphism in ERAP1 is associated with susceptibility to ankylosing spondylitis in a Turkish population Rheumatology International ·Muhammet Çınar,汉初,Sedat Yılmaz,İsmail Şimşek,Mutlu Karkucak,Rahşan Ilıkçı Sağkan,Aysel Pekel,Hakan Erdem,İsmail Yaşar Avcı,Cengizhan Açıkel,Uğur Muşabak,Yusuf Tunca,Salih Pay	2013	18
10	Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab Therapeutics and Clinical Risk Management ·İsmail Şimşek,Sedat Yılmaz	2013	8
11	Thoughts and perceptions of ankylosing spondylitis patients with regard to TNF inhibitors Rheumatology International ·Fatma İlknur Çınar,Muhammet Çınar,Sedat Yılmaz,İsmail Şimşek,Hakan Erdem,Salih Pay	2013	6
12	Limbus vertebra Arthritis & Rheumatism ·Hatice Tuba Sanal,Sedat Yılmaz,İsmail Şimşek	2012	8
13	Value of DWI in visual assessment of activity of sacroiliitis in longstanding ankylosing spondylitis patients Skeletal Radiology ·Hatice Tuba Sanal,Sedat Yılmaz,Umut Kalyoncu,Muhammet Çınar,İsmail Şimşek,Hakan Erdem,Salih Pay,Ayhan Dinç,Cem Tayfun	2012	16
14	Treatment options for rheumatoid arthritis beyond TNF-α inhibitors Expert Review of Clinical Pharmacology ·Yusuf Yazıcı,İsmail Şimşek	2010	3
15	Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis? Rheumatology International ·Hakan Erdem,Salih Pay,Uğur Muşabak,İsmail Şimşek,Ayhan Dinç,Aysel Pekel,Ali Şengül	2007	15
16	Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment—case report Clinical Rheumatology ·İsmail Şimşek,Salih Pay,Ayhan Dinç,Hakan Erdem,Bülent Kurt	2006	7
17	Autosomal dominant periodic fever with AA amyloidosis: Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Turkish family Journal of Nephrology ·Ayhan Dinç,Hakan Erdem,Dorota Rowczenio,İsmail Şimşek,Salih Pay,Muhterem Bahçe,Helen J. Lachmann	2005	9
18	Chimerical Anti-TNF-α, Infliximab, Inhibits Neutrophil Chemotaxis and Production of Reactive Oxygen Species by Blocking the Priming Effect of Mononuclear Cells on Neutrophils Immunopharmacology and Immunotoxicology ·S. Pay,Uğur Muşabak,Hatice Rana Erdem,İsmail Şimşek,HungThanh Truong,A. Şengül,A Dinç	2005	14
19	Inhibition of Inducible Nitric Oxide Synthase Reduces Bacterial Translocation in a Rat Model of Acute Pancreatitis Pancreas ·İsmail Şimşek,Dilip Kiling,Mehmet Yaşar,Mustafa Özyurt,佳秀貞包,Salih Deveci,Bilgin Cömert,Ahmet Başustaoğlu,知之山下	2001	28
20	Sulfasalazine-induced Angioimmunoblastic lymphadenopathy developing in a patient with juvenile chronic arthritis Rheumatology International ·Kamalkumaran PR,A Dinç,İsmail Şimşek,光成金,Hakan Erdem	2000	10

About İsmail Şimşek

İsmail Şimşek is a scholar working on Rheumatology, Anatomy, Nephrology, Ophthalmology and Hematology, having authored 54 papers that have together received 697 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (18 papers), Systemic Lupus Erythematosus Research (9 papers), Spondyloarthritis Studies and Treatments (8 papers), Inflammasome and immune disorders (7 papers), Ocular Diseases and Behçet’s Syndrome (6 papers), Osteoarthritis Treatment and Mechanisms (6 papers), Autoimmune and Inflammatory Disorders Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Rheumatology (340 citations), Hematology (81 citations), Immunology (132 citations), Pharmacology (102 citations) and Ophthalmology (48 citations). İsmail Şimşek has collaborated with scholars based in Türkiye, United States and Serbia. Frequent co-authors include Hakan Erdem, Ayhan Dinç, Salih Pay, Yusuf Yazıcı, Sedat Yılmaz, J. Tambiah, Allan Gibofsky, A. DiFrancesco, Nancy E. Lane and Christopher J. Swearingen. Their work appears in journals such as Annals of the Rheumatic Diseases, Clinical Rheumatology, Rheumatology and Therapy, Journal of Nephrology and Pancreas.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact